Aravive (NASDAQ:ARAV) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Aravive (NASDAQ:ARAV) posted its quarterly earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.04), Fidelity Earnings reports.

Aravive stock traded up $0.01 during trading hours on Friday, hitting $6.53. 5,300 shares of the stock were exchanged, compared to its average volume of 23,717. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.28 and a current ratio of 11.28. The stock has a market capitalization of $75.95 million, a P/E ratio of -0.61 and a beta of 2.17. Aravive has a 12 month low of $3.07 and a 12 month high of $9.72. The business’s 50-day moving average is $7.03 and its two-hundred day moving average is $6.27.

In other Aravive news, CEO Jay Shepard sold 4,004 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $6.82, for a total transaction of $27,307.28. 39.80% of the stock is currently owned by corporate insiders.

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of Aravive in a research report on Friday. Piper Jaffray Companies set a $15.00 price target on shares of Aravive and gave the stock a “buy” rating in a research report on Friday, September 27th. ValuEngine raised shares of Aravive from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Zacks Investment Research lowered shares of Aravive from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $13.69.

About Aravive

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Recommended Story: What is Cost of Debt?

Earnings History for Aravive (NASDAQ:ARAV)

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with's FREE daily email newsletter.